These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 33553221)
21. Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies. Hidayat K; Du X; Shi BM Osteoporos Int; 2019 Oct; 30(10):1923-1940. PubMed ID: 31134305 [TBL] [Abstract][Full Text] [Related]
22. Preventing the development and progression of diabetic kidney disease: Where do we stand? Zagkotsis G; Markou M; Paschou E; Papanikolaou P; Sabanis N Diabetes Metab Syndr; 2018 Jul; 12(4):585-590. PubMed ID: 29602760 [TBL] [Abstract][Full Text] [Related]
23. Multidisciplinary management of diabetic kidney disease: a systematic review and meta-analysis. Helou N; Dwyer A; Shaha M; Zanchi A JBI Database System Rev Implement Rep; 2016 Jul; 14(7):169-207. PubMed ID: 27532796 [TBL] [Abstract][Full Text] [Related]
24. Histone demethylase UTX is a therapeutic target for diabetic kidney disease. Chen H; Huang Y; Zhu X; Liu C; Yuan Y; Su H; Zhang C; Liu C; Xiong M; Qu Y; Yun P; Zheng L; Huang K J Physiol; 2019 Mar; 597(6):1643-1660. PubMed ID: 30516825 [TBL] [Abstract][Full Text] [Related]
25. Epidermal Growth Factor Receptor: A Potential Therapeutic Target for Diabetic Kidney Disease. Sheng L; Bayliss G; Zhuang S Front Pharmacol; 2020; 11():598910. PubMed ID: 33574751 [TBL] [Abstract][Full Text] [Related]
26. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease. Mima A J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432 [TBL] [Abstract][Full Text] [Related]
27. Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function". Pugliese G; Penno G; Natali A; Barutta F; Di Paolo S; Reboldi G; Gesualdo L; De Nicola L; Nutr Metab Cardiovasc Dis; 2019 Nov; 29(11):1127-1150. PubMed ID: 31586514 [TBL] [Abstract][Full Text] [Related]
28. Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study. Knudsen JS; Baggesen LM; Lajer M; Nurkanovic L; Ustyugova A; Sørensen HT; Thomsen RW PLoS One; 2020; 15(3):e0229621. PubMed ID: 32130249 [TBL] [Abstract][Full Text] [Related]
30. Influence of IL-6, IL-10, IFN-γ and TNF-α genetic variants on susceptibility to diabetic kidney disease in type 2 diabetes mellitus patients. Fathy SA; Mohamed MR; Ali MAM; El-Helaly AE; Alattar AT Biomarkers; 2019 Feb; 24(1):43-55. PubMed ID: 30015512 [TBL] [Abstract][Full Text] [Related]
31. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury. Penno G; Garofolo M; Del Prato S Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869 [TBL] [Abstract][Full Text] [Related]
32. Micheliolide ameliorates diabetic kidney disease by inhibiting Mtdh-mediated renal inflammation in type 2 diabetic db/db mice. Liu W; Chen X; Wang Y; Chen Y; Chen S; Gong W; Chen T; Sun L; Zheng C; Yin B; Li S; Luo C; Huang Q; Xiao J; Xu Z; Peng F; Long H Pharmacol Res; 2019 Dec; 150():104506. PubMed ID: 31669149 [TBL] [Abstract][Full Text] [Related]
33. Pentoxifylline for Diabetic Nephropathy: an Important Opportunity to Re-purpose an Old Drug? Bhanot S; Leehey DJ Curr Hypertens Rep; 2016 Jan; 18(1):8. PubMed ID: 26747265 [TBL] [Abstract][Full Text] [Related]
34. Early intervention with mesenchymal stem cells prevents nephropathy in diabetic rats by ameliorating the inflammatory microenvironment. Li Y; Liu J; Liao G; Zhang J; Chen Y; Li L; Li L; Liu F; Chen B; Guo G; Wang C; Yang L; Cheng J; Lu Y Int J Mol Med; 2018 May; 41(5):2629-2639. PubMed ID: 29484379 [TBL] [Abstract][Full Text] [Related]
35. Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies. Warren AM; Knudsen ST; Cooper ME Expert Opin Ther Targets; 2019 Jul; 23(7):579-591. PubMed ID: 31154867 [No Abstract] [Full Text] [Related]
36. Rationale and strategies for early detection and management of diabetic kidney disease. Radbill B; Murphy B; LeRoith D Mayo Clin Proc; 2008 Dec; 83(12):1373-81. PubMed ID: 19046557 [TBL] [Abstract][Full Text] [Related]
37. Indications for renal biopsy in patients with diabetes. Joint position statement of the Italian Society of Nephrology and the Italian Diabetes Society. Di Paolo S; Fiorentino M; De Nicola L; Reboldi G; Gesualdo L; Barutta F; Natali A; Penno G; Fioretto P; Pugliese G; Nutr Metab Cardiovasc Dis; 2020 Nov; 30(12):2123-2132. PubMed ID: 33239162 [TBL] [Abstract][Full Text] [Related]
38. The imidazopyridine derivative X22 prevents diabetic kidney dysfunction through inactivating NF-κB signaling. Jiang Y; Yang L; Yang X; Yin S; Zhuang F; Liu Z; Wang Y; Liang G; Qian J Biochem Biophys Res Commun; 2020 May; 525(4):877-882. PubMed ID: 32171523 [TBL] [Abstract][Full Text] [Related]